Adaptive Biotechnologies Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ADPT research report →
About the company
Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in Seattle, Washington (operating as Adaptive TCR Corporation until its name change in December 2011), is a commercial-stage entity focused on pioneering an immune medicine platform. This advanced platform is engineered for the precise diagnosis and effective treatment of a broad spectrum of illnesses. The company offers several core technological solutions.
- CEO
- Chad Robins
- IPO
- 2019
- Employees
- 619
- HQ
- Seattle, WA, US
Price Chart
- Market Cap
- $3.39B
- P/E
- -64.72
- P/S
- 11.48
- P/B
- 15.23
- EV/EBITDA
- -159.87
- Div Yield
- 0.00%
- Gross Margin
- 75.26%
- Op Margin
- -15.82%
- Net Margin
- -16.82%
- ROE
- -24.26%
- ROIC
- -10.78%
- Revenue
- $276.98M · 54.77%
- Net Income
- $-59,499,000 · 62.69%
- EPS
- $-0.39 · 63.89%
- Op Income
- $-57,123,000
- FCF YoY
- 50.50%
- 52W High
- $22.80
- 52W Low
- $9.96
- 50D MA
- $15.90
- 200D MA
- $15.79
- Beta
- 2.07
- Avg Volume
- 2.49M
Get TickerSpark's AI analysis on ADPT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 29, 26 | BENZENO SHARON | other | 51,570 |
| Jun 29, 26 | BENZENO SHARON | other | 24,944 |
| Jun 29, 26 | BENZENO SHARON | other | 24,944 |
| Jun 26, 26 | BENZENO SHARON | other | 11,034 |
| Jun 29, 26 | BENZENO SHARON | other | 1,837 |
| Jun 26, 26 | BENZENO SHARON | sell | 11,034 |
| Jun 29, 26 | BENZENO SHARON | sell | 154,768 |
| Jun 29, 26 | BENZENO SHARON | other | 51,570 |
| Jun 29, 26 | BENZENO SHARON | other | 24,944 |
| Jun 29, 26 | BENZENO SHARON | other | 24,944 |
Our ADPT coverage
Recent articles, reports, and earnings notes.
No research on ADPT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ADPT report →Similar companies
Peers in the same neighborhood.